Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead

Neuroendocrinology

Volumn 96, Issue 4, 2012, Pages 261-271

  Sundin, Anders ^a   Rockall, Andrea ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

11C 5 hydroxytryptophan; 18F labelled L DOPA; 68Ga; Computed tomography; Imaging; Neuroendocrine tumors; PERCIST; Positron emission tomography; RECIST; Response criteria

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DOTATOC GA 68; FLUORODEOXYGLUCOSE F 18; LEVODOPA; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; SORAFENIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL TUMOR; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; MEDICAL EXPERT; MEDICAL LITERATURE; MEDLINE; MOLECULAR IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANIMALS; DIAGNOSTIC IMAGING; GASTROINTESTINAL NEOPLASMS; HUMANS; MONITORING, PHYSIOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 84871612736     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000342270     Document Type: Review

References (55)

1. Yao JC, Hassan M, Phan A, et al: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Turaga KK, Kvols LK: Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2011; 61:113-132.
3. Rinke A, Muller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-4663.
4. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metra-kos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-513, erratum: N Engl J Med 2011; 364:1082.
5. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
6. Kwekkeboom DJ, de Herder WW, Krenning EP: Somatostatin receptor-targeted radionu-clide therapy in patients with gastroentero-pancreatic neuroendocrine tumors. Endo-crinol Metab Clin North Am 2011; 40:173-185.
7. Rockall AG, Reznek RH: Imaging of neuroendocrine tumors (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21:43-68.
8. Rockall AG, Planche K, Power N, Nowosin-ska E, Monson JP, Grossman AB, et al: Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI. Neuroendo-crinology 2009; 89:288-295.
9. Sundin A, Vullierme MP, Kaltsas G, Plock-inger U: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuro-endocrinology 2009; 90: 167-183.
10. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL: North American Neuroendocrine Tumor Society (NANETS): NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010; 39: 713-734.
11. Sundin A, Garske U, Orlefors H: Nuclear imaging of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21: 69-85.
12. World Health Organization: WHO Handbook for Reporting Results of Cancer treatment. WHO Offset Publication No. 48 (pamphlet). Geneva, World Health Organization, 1979.
13. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10:239-253.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
16. Schwartz LH, Bogaerts J, Ford R, et al: Eva lu-ation of lymph nodes with RECIST 1.1. Eur J Ca ncer 2009; 45: 261-267.
17. Padhani AR, Ollivier L: The RECIST (Response Evaluation Criteria in Solid Tumours) criteria: implications for diagnostic radiologists. Br J Radiol 2001; 74: 983-986.
18. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C: Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006; 26: 481-495.
19. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with ima-tinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759.
20. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
21. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
22. 18 F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med 2003; 44: 192-197.
23. Bentzen SM: Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005; 6:112-117.
24. Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, Manchul L, et al: Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 2001; 61:6400-6405.
25. Torigian DA, Alavi A: The evolving role of structural and functional imaging in assessment of age-related changes in the body. Semin Nucl Med 2007; 37: 64-68.
26. Higgins LJ, Pomper MG: The evolution of imaging in cancer: current state and future challenges. Semin Oncol 2011; 38:3-15.
27. 18 F-FLT PET in non-small cell lung cancer. J Nucl Med 2010; 51: 1870-1877.
28. 18F]-f luorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
29. 18 F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47:1059-1066.
30. Wahl RL, Jacene H, Kasamon Y, Lodge MA: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 Suppl 1: 122S-150S.
31. Boellaard R, O'Doherty MJ, Weber WA, et al: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
32. 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with soma-tostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
33. 68 Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor- mediated radionuclide therapy. J Nucl Med 2009; 50:1427-1434.
34. 68 Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Biol Med 2010; 51: 1349-1356.
35. 68 Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010; 37: 2004-2010.
36. 18 F-FDG PET. J Nucl Med 2010; 51: 704-712.
37. 18 F-FDG. Cancer 2008; 112:2447-2455.
38. 18 F-f luorodeox yglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16:978-985.
39. 18 F-FDG PET and somatostatin receptor scintigraphy in patients with meta-static endocrine tumors. J Nucl Med 2009; 50: 858-864.
40. Pearse AG: The APUD concept and hormone production. Clin Endocrinol Metab 1980; 9: 211-222.
41. Orlefors H, Sundin A, Ahlstrom H, et al: Positron emission tomography with 5-hydroxy-tryprophan in neuroendocrine tumors. J Clin Oncol 1998; 16:2534-2541.
42. 11 C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33:60-65.
43. 11 C-5-hydroxy-trypto-phan positron emission tomography. J Clin Oncol 2008; 26: 1489-1495.
44. 18 F]fluorodihy-droxyphenylalanine PET/CT for imaging of neuroendocrine tumours. Br J Surg 2010; 97: 691-697.
45. 18F]fluoro-dihydroxy-phenylalanine positron emission tomography in primary diagnosis, staging, and re-staging of neuroendocrine tumors. Endocr Relat Cancer 2009; 16:255-265.
46. 18 F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009; 36:765-770.
47. Putzer D, Gabriel M, Kendler D, et al: Comparison of (68)Ga-DOTA-Tyr(3)- octreotide and (18)F-fluoro-L-dihydroxyphenylala-nine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010; 54:68-75.
48. 18 F-DOPA PET for the detection of gas-tro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 1431-1438.
49. Bergström M, Eriksson B, Oberg K, et al: In vivo demonst rat ion of enzy me activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med 1996; 37: 32-37.
50. Yopp AC, Schwartz LH, Kemeny N, et al: An-tiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. Ann Surg Oncol 2011; 18: 2192-2199.
51. Goh V, Dattani M, Farwell J, et al: Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis. Eur Radiol 2011; 21:974-981.
52. Koh TS, Thng CH, Hartono S, et al: Dynamic contrast-enhanced MRI of neuroendocrine hepatic metastases: a feasibility study using a dual-input two-compartment model. Magn Reson Imaging 2011; 65: 250-260.
53. Ng CS, Raunig DL, Jackson EF et al: Repro-ducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol 2010; 194:W134-W140.
54. Chenevert TL, Meyer CR, Moffat BA, et al: Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Immunol 2002; 1:336-343.
55. Pickles MD, Gibbs P, Lowry M, Turnbull LW: Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24: 843-847.